| |
Oncotype Dx-tested
|
Oncotype Dx-eligible
|
|---|
| |
OR
|
(95% CI)
|
P
|
OR
|
(95% CI)
|
P
|
|---|
|
Recurrence score
| | |
0.02
| | | |
|
Low (ref)
| | | | | | |
|
Intermediate
|
0.98
|
(0.64–1.50)
| | | | |
|
High
|
0.40
|
(0.20–0.81)
| | | | |
|
Tested
| | | | | |
<0.001
|
|
Yes
| | | |
2.48
|
(2.03–3.04)
| |
|
No (ref)
| | | | | | |
|
Year diagnosed
| | |
0.13
| | |
0.004
|
|
2006–2007 (ref)
| | | | | | |
|
2008–2009
|
0.74
|
(0.49–1.13)
| |
0.74
|
(0.61–0.89)
| |
|
2010–2012
|
1.17
|
0.65–2.09)
| |
0.89
|
(0.70–1.15)
| |
|
Age at diagnosis
| | |
0.20
| | |
<0.001
|
|
24–39
|
0.49
|
(0.24–1.01)
| |
0.59
|
(0.43–0.82)
| |
|
40–49
|
0.73
|
(0.48–1.11)
| |
0.74
|
(0.60–0.90)
| |
|
50–59 (ref)
| | | | | | |
|
60–63
|
0.80
|
(0.49–1.30)
| |
1.01
|
(0.80–1.27)
| |
|
Race-ethnicity
| | |
0.06
| | |
0.19
|
|
NH white (ref)
| | | | | | |
|
NH black
|
3.62
|
(0.83–15.81)
| |
0.92
|
(0.61–1.38)
| |
|
Hispanic
|
0.62
|
(0.27–1.41)
| |
0.89
|
(0.60–1.33)
| |
|
Other
|
2.52
|
(0.89–7.13)
| |
1.44
|
(1.01–2.06)
| |
|
Marital status
| | |
0.16
| | |
0.12
|
|
Married (ref)
| | | | | | |
|
Not married
|
0.76
|
(0.52–1.11)
| |
0.87
|
(0.72–1.04)
| |
|
Prior cancer
| | |
0.65
| | |
0.84
|
|
No (ref)
| | | | | | |
|
Yes
|
1.21
|
(0.52–2.80)
| |
1.04
|
(0.71–1.53)
| |
|
State
| | | | | |
0.004
|
|
CA (ref)
| | | | | | |
|
GA
|
0.62
|
(0.32–1.20)
| |
1.15
|
(0.85–1.55)
| |
|
KY
|
1.73
|
(0.72–4.14)
| |
1.71
|
(1.19–2.47)
| |
|
NY
|
1.05
|
(0.50–2.19)
| |
1.60
|
(1.16–2.20)
| |
|
OH
|
1.20
|
(0.58–2.50)
| |
1.45
|
(1.05–2.00)
| |
|
Area
| | |
0.74
| | |
0.70
|
|
Rural (ref)
| | | | | | |
|
Urban
|
1.17
|
(0.47–2.92)
| |
1.08
|
(0.74–1.56)
| |
|
Median household income
| | |
0.24
| | |
0.07
|
|
1 (lowest (ref))
| | | | | | |
|
2
|
1.23
|
(0.68–2.22)
| |
0.96
|
(0.74–1.26)
| |
|
3
|
1.00
|
(0.57–1.76)
| |
0.97
|
(0.74–1.26)
| |
|
4
|
1.84
|
(0.97–3.49)
| |
1.35
|
(1.02–1.82)
| |
|
5 (highest)
|
1.10
|
0.59–2.07)
| |
1.01
|
(0.75–1.36)
| |
|
Stage
| | |
0.14
| | |
0.52
|
|
I (ref)
| | | | | | |
|
II
|
0.71
|
(0.45–1.12)
| |
0.92
|
(0.71–1.19)
| |
|
Nodal involvement
| | |
0.22
| | |
0.10
|
|
N0
|
0.42
|
(0.14–1.26)
| |
0.87
|
(0.64–1.17)
| |
|
N1mic
|
0.69
|
(0.18–2.62)
| |
1.40
|
(0.91–2.17)
| |
|
N1 (ref)
| | | | | | |
|
HER2 status
| | |
0.82
| | |
0.33
|
|
Negative
|
0.89
|
(0.49–1.62)
| |
1.21
|
(0.55–2.92)
| |
|
Borderline
|
0.63
|
(0.13–3.06)
| |
1.26
|
(0.94–1.56)
| |
|
Unknown (ref)
| | | | | | |
|
Hormone receptor status
| | | | | |
<0.001
|
|
ER and PR both positive (ref)
| | | | | | |
|
Only ER or PR positive
|
0.80
|
(0.45–1.42)
| |
0.58
|
(0.47–0.72)
| |
|
Histological grade
| | |
0.52
| | |
<0.001
|
|
1–2 (well/moderately differentiated (ref)
| | | | | | |
|
3 (poorly or not differentiated)
|
1.18
|
(0.71–1.96)
| |
0.68
|
(0.56–0.84)
| |
|
One year comorbidities
| | |
0.57
| | |
0.51
|
|
0 (ref)
| | | | | | |
|
1 or more
|
0.86
|
(0.52–1.43)
| |
0.92
|
(0.72–1.18)
| |
|
Surgery type
| | |
0.74
| | |
0.42
|
|
Breast-conserving surgery (ref)
| | | | | | |
|
Mastectomy
|
0.94
|
(0.47–2.92)
| |
0.93
|
(0.78–1.11)
| |
|
Chemotherapy
| | |
0.10
| | | |
|
No (ref)
| | | | | | |
|
Yes
|
1.49
|
(0.92–2.39)
| | | | |
|
Chemotherapy
|
Tested
| | | | | |
<0.001
|
|
No
|
Yes
|
--
| | |
3.25
|
(2.53–4.16)
| |
|
No
|
--
| | | | | |
|
Yes
|
Yes
|
--
| | |
1.35
|
(0.96–1.90)
| |
|
No
|
--
| | | | | |
- Nodal involvement: N0 no cancer in the lymph nodes; N1mic lymph node cancer that can only be seen under a microscope (<2 mm in size); N1 cancer at least 2 mm in size in at least one of three axillary lymph nodes. ref reference, NH non-Hispanic, HER2 human epidermal growth factor receptor 2, ER estrogen receptor, PR progesterone receptor
